Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&U Colestid OTC development investment of over $6 mil. includes consumer use study.

This article was originally published in The Tan Sheet

Executive Summary

COLESTID OTC DEVELOPMENT INVESTMENT OF OVER $6 MIL. since 1989 includes expenditures on a consumer use study in several major urban markets, according to Pharmacia & Upjohn. The company initiated the study in January and expects to complete the project at the end of 1997. Information regarding the company's program to switch its prescription cholesterol-reducing drug Colestid (colestipol) to OTC status was disclosed by Pharmacia & Upjohn in a trademark infringement lawsuit filed against Pharmanex last spring in Grand Rapids, Mich. federal court.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel